Physician profile
Irving E Ingraham
NPI 1073569760
$3,727.72
in general payments reported to CMS, 2019-2025
14 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $65.91 · 2022: $639 · 2023: $1,015 · 2024: $589 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $70.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.46 |
| Education | $70.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,185.91 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $490.29 | 2019-2024 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $442.49 | 2019-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $270.37 | 2023 | Zeposia |
| Janssen Biotech, INC. | $246.90 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.31 | 2019-2025 | Xifaxan |
| Pfizer INC. | $157.69 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $132.00 | 2022 | |
| Ucb, INC. | $124.80 | 2019 | |
| Ardelyx, INC. | $115.85 | 2023 | Ibsrela |
| Genzyme Corporation | $111.33 | 2024 | |
| Gilead Sciences, INC. | $107.67 | 2024-2025 | Epclusa, Livdelzi |
| Regeneron Healthcare Solutions, INC. | $104.35 | 2023 | |
| Endogastric Solutions, INC | $31.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irving Ingraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.